Immuron Announces Publication Of Data From Its Phase 2 Clinical Trial Of Once-Daily Oral Travelan In 'Scientific Reports'; Statistically Significant 50% Reduction In ETEC Challenge-Related Adverse Events Versus Placebo

뉴스 본문을 불러오고 있어요.

Immuron Announces Publication Of Data From Its Phase 2 Clinical Trial Of Once-Daily Oral Travelan In 'Scientific Reports'; Statistically Significant 50% Reduction In ETEC Challenge-Related Adverse Events Versus Placebo | 웨이프 WAPE

Immuron Announces Publication Of Data From Its Phase 2 Clinical Trial Of Once-Daily Oral Travelan In 'Scientific Reports'; Statistically Significant 50% Reduction In ETEC Challenge-Related Adverse Events Versus Placebo

기사 요약

관련 종목

웨이프 AI가 분석했어요.

Immuron이 Travelan의 임상 2상에서 통계적으로 유의미한 부작용 감소 데이터를 발표함

댓글 —